

QUESTION

For convenience, most questions are multiple choice, with space for extra details where relevant. In each case please mark all that apply

1. Do you currently offer a biomarker testing for the following, as of the beginning of 2018?

PD-L1 in NSCLC

Yes, in house service

Yes, but send out PD-L1 testing to another laboratory

(Please specify which laboratory samples are sent to: Liverpool Clinical Laboratories)

No, and do not send to another laboratory

ALK in NSCLC

Yes, in house service

Yes, but send out ALK testing to another laboratory

(Please specify which laboratory samples are sent to: Christie Hospital)

No, and do not send to another laboratory

BRAF in Melanoma

Yes, in house service

Yes, but send out BRAF testing to another laboratory

(Please specify which laboratory samples are sent to: Christie Hospital)

No, and do not send to another laboratory

2. Is predictive biomarker testing conducted at the same lab (or similar location such as in same building) as the initial cytological and histological (H&E stain) assessment, or is this done at a different site?

IHC

Yes, done at same lab or site

No, sent to another lab or site

(Please specify which laboratory samples are sent to: Christie Hospital)

FISH /ISH/ NGS / PCR

Yes, done at same lab or site

No, sent to another lab or site

(Please specify which laboratory samples are sent to:Christie Hospital)

3. Is biomarker testing performed reflexively or upon request for the following biomarkers?

PD-L1 in NSCLC

Reflexively (i.e. prior to starting 1L treatment)

Upon request (i.e. case by case after disease progression)

If reflexively – What is the laboratory protocol for PD-L1 testing in lung cancer patients?

Multi-marker panel (i.e. multiple biomarkers, one test)

Sequential single gene (i.e. one biomarker, one test)

Other (Please specify_____)

ALK for NSCLC

Reflexively (i.e. prior to starting 1L treatment)

Upon request (i.e. case by case after disease progression)

If reflexively – What is the laboratory protocol for ALK testing in lung cancer patients?

Multi-marker panel (i.e. multiple biomarkers, one test)

Sequential single gene (i.e. one biomarker, one test)

Other (Please specify_____)

BRAF in Melanoma

Reflexively (i.e. prior to starting 1L treatment)

Upon request (i.e. case by case after disease progression)

If reflexively – What is the laboratory protocol for BRAF testing in melanoma patients?

Multi-marker panel (i.e. multiple biomarkers, one test)

Sequential single gene (i.e. one biomarker, one test)

Other (Please specify_____)

4. Which of the following biomarkers are assessed in lung cancer patients in your laboratory? (please select all that apply)

ALK
EGFR
ROS1
DLL3
PDL-1

5. Which of the following testing platforms are used at this this laboratory? (please select all that apply)

FISH
NGS
PCR
IHC
Other

6. What IHC staining platform(s) are used in the laboratory for biomarker testing? (please select all that apply)

Ventana
Dako
Leica
Other (If possible, please supply the model of the platform_____)

7. What type of test does the institution prefer to use for biomarker-predictive IHCs?

IVD CDx (commercial)
LDT (lab developed)
None

What is the main factor in this decision?

Funding constraints
Control over methodology
Other (Please specify: Network Guidelines)

8. Does your lab / trust seek separate reimbursement from NHS under the “high-cost medicines and tests” provision for biomarker tests that have been excluded from tariff?

Yes

No

- 9. What is the number of samples being tested (or sent-out) are tested for the following biomarkers?**

ALK

Please specify number: 2 – 4 (per month)

EGFR

Please specify number: 2- 4 (per month)

PD-L1

Please specify number: 2- 4 (per month)

BRAF

Please specify number: 1-2 (per month)

- 10. Where are archived tissues from lung cancer patients stored?**

On-site

Off-site

- 11. If on-site; how long are tissues stored on site until transferred to other storage facility?**

Never

<1 yr

1-2 yrs

>2 yrs

- 12. What is the typical turn-around time from tissue/specimen extraction to the report of biomarker testing results in lung cancer patients?**

<1 week

1 – 2 weeks

>2 weeks

- 13. How are the following biomarker testing funded at your lab?**

Local funding (financed through pathology / lab budget)

Pharma funded initiative, please specify details

Individual funding through high cost medicines and procedures provision

Unsure

RESPONSE:

1. Yes, but send out PD-L1 testing to another laboratory
(Please specify which laboratory samples are sent to: Liverpool Clinical Laboratories)
Yes, but send out ALK testing to another laboratory
(Please specify which laboratory samples are sent to: Christie Hospital)
Yes, but send out BRAF testing to another laboratory
(Please specify which laboratory samples are sent to: Christie Hospital)
2. No, sent to another lab or site
(Please specify which laboratory samples are sent to: Christie Hospital)
No, sent to another lab or site
(Please specify which laboratory samples are sent to: Christie Hospital)
3. Upon request (i.e. case by case after disease progression)
Reflexively (i.e. prior to starting 1L treatment) - Sequential single gene (i.e. one biomarker, one test)
Upon request (i.e. case by case after disease progression)
4. None
5. IHC
6. Ventana
7. None
8. No
9. ALK
Please specify number: 2 – 4 (per month)
EGFR
Please specify number: 2- 4 (per month)
PD-L1
Please specify number: 2- 4 (per month)
BRAF
Please specify number: 1-2 (per month)
10. Off-site
11. 1-2 yrs

12. 1 – 2 weeks

13. Unsure

ATTACHMENT: No